Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF cohort

Brennan Spiegel, Lucinda Harris, Susan Lucak, Emeran Mayer, Bruce Naliboff, Roger Bolus, Eric Esrailian, William D. Chey, Anthony Lembo, Hetal Karsan, Kirsten Tillisch, Gareth Dulai, Jennifer Talley, Lin Chang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

OBJECTIVES: A utility is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities.METHODS:We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohorta longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months.RESULTS:There were 257 patients (79% women; age43±15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P < 0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r0.31; P<0.01), IBSSS (r0.36; P<0.01), IBS-QOL (r0.36; P<0.01), CDC-4 (r0.44; P<0.01), WPAI presenteeism (r0.16; P<0.01), abdominal pain (r0.43; P<0.01), and distension (r0.18; P<0.01). The utilities in patients reporting considerable relief of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P<0.02).CONCLUSIONS:EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.

Original languageEnglish (US)
Pages (from-to)1984-1991
Number of pages8
JournalAmerican Journal of Gastroenterology
Volume104
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Irritable Bowel Syndrome
Health
Cost-Benefit Analysis
Patient Reported Outcome Measures
Quality of Life
Centers for Disease Control and Prevention (U.S.)
Economics
Efficiency
Constipation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Developing valid and reliable health utilities in irritable bowel syndrome : Results from the IBS PROOF cohort. / Spiegel, Brennan; Harris, Lucinda; Lucak, Susan; Mayer, Emeran; Naliboff, Bruce; Bolus, Roger; Esrailian, Eric; Chey, William D.; Lembo, Anthony; Karsan, Hetal; Tillisch, Kirsten; Dulai, Gareth; Talley, Jennifer; Chang, Lin.

In: American Journal of Gastroenterology, Vol. 104, No. 8, 08.2009, p. 1984-1991.

Research output: Contribution to journalArticle

Spiegel, B, Harris, L, Lucak, S, Mayer, E, Naliboff, B, Bolus, R, Esrailian, E, Chey, WD, Lembo, A, Karsan, H, Tillisch, K, Dulai, G, Talley, J & Chang, L 2009, 'Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF cohort', American Journal of Gastroenterology, vol. 104, no. 8, pp. 1984-1991. https://doi.org/10.1038/ajg.2009.232
Spiegel, Brennan ; Harris, Lucinda ; Lucak, Susan ; Mayer, Emeran ; Naliboff, Bruce ; Bolus, Roger ; Esrailian, Eric ; Chey, William D. ; Lembo, Anthony ; Karsan, Hetal ; Tillisch, Kirsten ; Dulai, Gareth ; Talley, Jennifer ; Chang, Lin. / Developing valid and reliable health utilities in irritable bowel syndrome : Results from the IBS PROOF cohort. In: American Journal of Gastroenterology. 2009 ; Vol. 104, No. 8. pp. 1984-1991.
@article{2c82d152d264426ea78892714028e8a3,
title = "Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF cohort",
abstract = "OBJECTIVES: A utility is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities.METHODS:We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohorta longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months.RESULTS:There were 257 patients (79{\%} women; age43±15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P < 0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r0.31; P<0.01), IBSSS (r0.36; P<0.01), IBS-QOL (r0.36; P<0.01), CDC-4 (r0.44; P<0.01), WPAI presenteeism (r0.16; P<0.01), abdominal pain (r0.43; P<0.01), and distension (r0.18; P<0.01). The utilities in patients reporting considerable relief of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P<0.02).CONCLUSIONS:EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.",
author = "Brennan Spiegel and Lucinda Harris and Susan Lucak and Emeran Mayer and Bruce Naliboff and Roger Bolus and Eric Esrailian and Chey, {William D.} and Anthony Lembo and Hetal Karsan and Kirsten Tillisch and Gareth Dulai and Jennifer Talley and Lin Chang",
year = "2009",
month = "8",
doi = "10.1038/ajg.2009.232",
language = "English (US)",
volume = "104",
pages = "1984--1991",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Developing valid and reliable health utilities in irritable bowel syndrome

T2 - Results from the IBS PROOF cohort

AU - Spiegel, Brennan

AU - Harris, Lucinda

AU - Lucak, Susan

AU - Mayer, Emeran

AU - Naliboff, Bruce

AU - Bolus, Roger

AU - Esrailian, Eric

AU - Chey, William D.

AU - Lembo, Anthony

AU - Karsan, Hetal

AU - Tillisch, Kirsten

AU - Dulai, Gareth

AU - Talley, Jennifer

AU - Chang, Lin

PY - 2009/8

Y1 - 2009/8

N2 - OBJECTIVES: A utility is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities.METHODS:We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohorta longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months.RESULTS:There were 257 patients (79% women; age43±15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P < 0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r0.31; P<0.01), IBSSS (r0.36; P<0.01), IBS-QOL (r0.36; P<0.01), CDC-4 (r0.44; P<0.01), WPAI presenteeism (r0.16; P<0.01), abdominal pain (r0.43; P<0.01), and distension (r0.18; P<0.01). The utilities in patients reporting considerable relief of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P<0.02).CONCLUSIONS:EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.

AB - OBJECTIVES: A utility is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities.METHODS:We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohorta longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months.RESULTS:There were 257 patients (79% women; age43±15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P < 0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r0.31; P<0.01), IBSSS (r0.36; P<0.01), IBS-QOL (r0.36; P<0.01), CDC-4 (r0.44; P<0.01), WPAI presenteeism (r0.16; P<0.01), abdominal pain (r0.43; P<0.01), and distension (r0.18; P<0.01). The utilities in patients reporting considerable relief of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P<0.02).CONCLUSIONS:EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.

UR - http://www.scopus.com/inward/record.url?scp=68349141680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349141680&partnerID=8YFLogxK

U2 - 10.1038/ajg.2009.232

DO - 10.1038/ajg.2009.232

M3 - Article

C2 - 19491835

AN - SCOPUS:68349141680

VL - 104

SP - 1984

EP - 1991

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -